Poxel SA (POXEL) AI Stock Analysis

• Market Cap: €13.43M
• Dividend Yield: N/A
• Average Volume (3M): 288.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 6
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 53,758,167
• 10 Day Avg. Volume: 262,495
• 30 Day Avg. Volume: 288,318
• PEG Ratio: <0.01
• Price to Book (P/B): -0.11
• Price to Sales (P/S): 1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: €0.37 ▲(62.17% Upside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is primarily constrained by weak financial performance—persistent losses, negative operating cash flow, and a highly stressed balance sheet with negative equity and rising debt. Technicals provide some support via recent upward momentum, but near-overbought readings add risk. Valuation remains challenged due to ongoing losses and no dividend information.

Positive Factors

Commercial partnership with Sumitomo Pharma

A revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.

Sharp revenue rebound in 2024

A material revenue inflection indicates commercial traction for marketed products or recognition of partnership receipts. Sustained top-line recovery over multiple quarters would improve operating leverage potential and validate the commercial model versus purely pre-revenue peers.

Focused metabolic/NASH clinical pipeline

A coherent R&D focus on diabetes and NASH leverages prior regulatory/commercial experience with imeglimin and targets large, structural markets. Small‑molecule assets can be more cost-efficient to develop and attract partnering/licensing opportunities, supporting multiple long-term value pathways.

Negative Factors

Highly stressed balance sheet

Deep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.

Persistent negative operating cash flow

Sustained negative operating cash flow means the company cannot self-fund growth and depends on partners, milestone receipts, or financing. That reliance impairs long‑term planning, elevates dilution risk, and could limit ability to scale commercialization or fund pivotal trials without external capital.

Ongoing unprofitability and volatile margins

Despite revenue gains, persistent negative profitability and historical margin swings indicate weak operating leverage and unstable unit economics. Over the medium term, sustainable value creation depends on consistent margin recovery and cost control, which are not yet demonstrated.

Poxel SA Business Overview & Revenue Model

Company Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

How the Company Makes Money

Poxel makes money primarily through (1) product-related income from TWYMEEG (imeglimin) in Japan via its partnership with Sumitomo Pharma—this has historically included milestone payments and other collaboration-related receipts tied to development, regulatory, and commercialization events, and may also include royalties or profit-sharing depending on the agreement terms (specific current terms not available: null); and (2) collaboration, licensing, and partnering revenue from out-licensing rights to its drug candidates in certain geographies or indications, which can generate upfront payments, development/regulatory/commercial milestones, and potential royalties on partner sales. As a clinical-stage biopharma, it may also generate limited ancillary income (e.g., research tax credits or grants) when available, but these are not core operating revenues and are not consistently disclosed as a primary revenue driver: null.

Poxel SA Financial Statement Overview

Summary

Despite a sharp revenue rebound in 2024, profitability remains weak with negative EBIT/EBITDA and large net losses. The balance sheet is highly stressed with deeply negative equity and rising debt, and operating cash flow is consistently negative—collectively indicating elevated funding/refinancing and dilution risk.

Income Statement

Revenue rebounded sharply in 2024 (up ~203% year over year), but profitability remains weak: EBIT and EBITDA are still negative and net losses are large across the full period. Earlier years show extreme margin volatility (very high gross profit in 2020–2021 versus near-zero gross profit in 2022–2023), highlighting an unstable earnings profile and limited operating leverage so far.

Balance Sheet

The balance sheet is highly stressed: stockholders’ equity is deeply negative in 2022–2024 (2024 equity about -€58.9M), while total debt has increased materially (to ~€69.7M in 2024). With negative equity and rising leverage, financial flexibility appears limited and refinancing/dilution risk is elevated.

Cash Flow

Cash generation remains a key concern, with operating cash flow consistently negative (roughly -€14M to -€26M per year, and about -€17.6M in 2024). Free cash flow has been volatile (positive in 2023 but negative in 2020–2022, and flat/zero in 2024 per the data), suggesting the business is still reliant on external funding rather than internally generated cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.66M	6.64M	1.98M	674.00K	13.40M	6.81M
Gross Profit	3.95M	3.66M	1.00K	2.00K	13.34M	6.81M
EBITDA	-3.07M	-4.32M	-12.17M	-28.02M	-22.52M	-29.71M
Net Income	-13.66M	-18.30M	-35.09M	-31.40M	-23.76M	-31.86M
Balance Sheet
Total Assets	5.00M	14.93M	4.82M	34.71M	54.89M	65.08M
Cash, Cash Equivalents and Short-Term Investments	2.06M	3.66M	2.34M	13.06M	32.29M	40.20M
Total Debt	60.99M	69.71M	47.03M	43.44M	35.14M	23.62M
Total Liabilities	66.41M	73.87M	53.90M	52.95M	46.68M	38.20M
Stockholders Equity	-61.40M	-58.94M	-49.10M	-18.24M	8.21M	27.07M
Cash Flow
Free Cash Flow	7.54M	0.00	3.05M	-21.84M	-16.94M	-26.03M
Operating Cash Flow	-7.21M	-17.61M	-13.98M	-21.81M	-16.89M	-25.75M
Investing Cash Flow	28.00K	92.00K	41.00K	-5.00K	-42.00K	52.00K
Financing Cash Flow	6.43M	18.82M	3.23M	2.58M	9.03M	28.71M

Poxel SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ALVAL	48 Neutral	€25.39M	-0.85	―	―	―	―
ALTHX	48 Neutral	€43.75M	-2.27	―	―	―	10.30%
ALDVI	47 Neutral	€26.35M	-0.86	―	―	101.95%	35.55%
POXEL	46 Neutral	€13.43M	-2.41	―	―	―	―
ABNX	43 Neutral	€111.32M	-10.72	-85.59%	―	-10.91%	-25.57%